Topics

Akcea, Pfizer Enter Licensing Agreement for Antisense Therapy

04:44 EDT 7 Oct 2019 | Contract Pharma

AKCEA-ANGPTL3-LRx is in Phase II development for the treatment of certain cardiovascular and metabolic diseases

Original Article: Akcea, Pfizer Enter Licensing Agreement for Antisense Therapy

NEXT ARTICLE

More From BioPortfolio on "Akcea, Pfizer Enter Licensing Agreement for Antisense Therapy"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...